Skip to main content
. 2017 Nov 27;55(12):3366–3373. doi: 10.1128/JCM.00865-17

FIG 4.

FIG 4

IgG and blockade titers against GII.4 (A and C) and GII.17 (B and D) norovirus from human sera from a GII.4 challenge study. Five pairs of prechallenge (day 0) and postchallenge (day 30) serum samples were used. The fold increases from acute- to convalescent-phase serum in IgG or blockade titers (green columns) were determined (right-hand y axis). No specific blockade (<25, set as 12.5) against the GII.17 variant attachment to the HBGAs was seen for either phase serum samples (D).